- PT217 is Phanes' first-in-class bispecific antibody
targeting DLL3 and CD47; atezolizumab
(TECENTRIQ®)
is Roche's anti-PD-L1 monoclonal antibody
- The clinical supply agreement
will focus on evaluating PT217 in combination with
atezolizumab for the treatment of small cell
lung cancer (SCLC), large cell neuroendocrine carcinoma of the lung
(LCNEC) and extrapulmonary neuroendocrine carcinomas (EP-NECs)
- PT217 was recently granted Fast Track designation by the
FDA for the treatment of patients with
extensive-stage small cell lung cancer (ES-SCLC) with disease
progression following platinum chemotherapy with or without a
checkpoint inhibitor
SAN
DIEGO, May 8, 2024 /PRNewswire/ -- Phanes
Therapeutics, Inc. (Phanes), a clinical stage biotech company
focused on innovative drug discovery and development in oncology,
announced today that it has entered into a clinical supply
agreement with Roche to study PT217, its first-in-class bispecific
antibody targeting DLL3 and CD47, in combination with Roche's
anti-PD-L1 therapy, atezolizumab, in patients with small cell
lung cancer (SCLC), large cell neuroendocrine carcinoma of the lung
(LCNEC) and extrapulmonary neuroendocrine carcinomas (EP-NECs).
PT217 was granted orphan drug designation (ODD) for the treatment
of SCLC by the FDA in 2022, and recently granted Fast Track
designation by the agency for the treatment of patients with
extensive-stage small cell lung cancer (ES-SCLC) with disease
progression following platinum chemotherapy with or without a
checkpoint inhibitor.
Phanes is currently enrolling patients in a multi-center Phase I
clinical trial of PT217. The Phase I clinical trial (NCT05652686),
known as the SKYBRIDGE study, is currently evaluating the safety,
tolerability, pharmacokinetics and preliminary efficacy of PT217 in
patients with advanced or refractory cancers expressing DLL3. The
next phase of Phanes' study is investigating the therapeutic
potential of PT217 as a combination therapy in SCLC, LCNEC and
EP-NECs. The clinical collaboration with Roche will evaluate PT217
in combination with atezolizumab in these patients.
"Phanes is very excited about partnering with Roche on this
novel approach to treat patients with SCLC, LCNEC and EP-NECs,"
said Rita Laeufle, MD, PhD, Chief Medical Officer (CMO) of Phanes.
"DLL3 is highly expressed in SCLC, LCNEC and EP-NECs and an
important target for treating these cancers. We believe the
mechanisms of PT217 and atezolizumab are complementary and the
combination has the potential to improve outcomes for patients.
This collaboration marks another milestone for Phanes in fulfilling
our vision of developing innovative approaches to treat
cancer."
TECENTRIQ® is a registered trademark of
Roche.
ABOUT PHANES THERAPEUTICS
Phanes Therapeutics, Inc. is a clinical stage biotech company
focused on innovative drug discovery and development in oncology.
Currently, it is conducting three Phase I clinical trials,
including the MORNINGSTAR study with its best-in-class monoclonal
antibody (mAb) program, PT199, the TWINPEAK study with PT886 and
the SKYBRIDGE study with PT217. Both PT886 and PT217 are
first-in-class bispecific antibodies and have been granted orphan
drug designation as well as Fast Track designation by the FDA.
The company has built a strong pipeline by leveraging its
proprietary technology platforms: PACbody®,
SPECpair® and ATACCbody® to develop novel
biologics that address high unmet medical needs in cancer.
For more information about Phanes Therapeutics, please visit
www.phanesthera.com
For business development or media inquiries, please contact
bd@phanestx.com or media@phanestx.com, respectively.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/phanes-therapeutics-inc-announces-clinical-supply-agreement-with-roche-to-evaluate-pt217-in-combination-with-an-anti-pd-l1-therapy-302140379.html
SOURCE Phanes Therapeutics